GSK has granted exclusive technology license for its clinical-stage Ebola vaccines to the Sabin Vaccine Institute, a US-based nonprofit organisation that promotes global vaccine development.
The agreements between GSK and Sabin in this regard are for advancing the development of the prophylactic candidate Ebola vaccines against the Ebola Zaire, Ebola Sudan and the Marburg virus.
Currently, there are no licensed vaccines are available against the three viruses, which are known to cause hemorrhagic fever with subsequent death in an average of 50% of cases, as per WHO fact sheets.
GSK Vaccines chief medical officer Thomas Breuer said: “These agreements with the Sabin Vaccine Institute are an important next step in the fight against Ebola and Marburg viruses.
“Enabling Sabin to build on the scientific progress GSK has delivered up to Phase II increases the likelihood these candidate vaccines may help prevent potential future outbreaks, and exemplifies GSK’s approach to global health vaccines which supports partners in taking forward our innovations in a sustainable way.”
